ZIOPHARM ONCOLOGY 8-K 2013
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): February 12, 2013
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
ZIOPHARM Oncology, Inc., or the Company, announced today that the Phase 3 trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma(PICASSO 3) has reached its target number of progression-free survival (PFS) events, and that top line data from PICASSO 3 will be announced by the Company during the last week of March 2013.
A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDEX OF EXHIBITS